The *Journal of Psychiatry & Neuroscience* is indexed according to the medical subject headings established by the National Library of Medicine, US National Institutes of Health.

The title for each article is followed by a code that designates the article’s category. The categories used in this volume are listed below.

La *Revue de psychiatrie & de neuroscience* est indexée par vedette-matière selon la nomenclature de la National Library of Medicine des National Institutes of Health américains.

Chaque titre d’article est suivi d’un code indiquant à quelle catégorie l’article appartient. Les catégories utilisées dans ce volume sont les suivantes:

- Brief Report / Rapport sommaire (Brief)
- CCNP News and Views / Nouvelles et opinions du CCNP (CCNP)
- Commentary /Commentaire (Comm)
- Editorial / Éditorial (E)
- Letter / Lettre (L)
- Psychopharmacology for the Clinician / Psychopharmacologie pratique (Psychopharm)
- Research Paper / Article de recherche (Res)
- Review Paper / Examen critique (Rev)

**-A-**

**Abnormalities**
- Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226

**Adrenoceptors**
- The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

**Affect**
- Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13
- Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

**Affective symptoms**
- Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res) 115

**Aggression**
- Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

**Alcohol**
- Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386

**Aldehyde load**
- Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

**Aldehyde sequestering agents**
- Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

**Alexithymia**
- Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res) 115

**Alzheimer disease**
- Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

**Neurodegeneration and aldehyde load: from concept to therapeutics**
- Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

**Amyotrophic lateral sclerosis**
- Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

**Animal models**
- Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326
- The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

**Anti-anxiety agents**
- The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

**Anticonvulsants**
- The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

**Antidepressants**
- Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects (Little and others) (Res) 333

**Antidepressive agents**
- Concerns regarding antidepressant use during pregnancy (Urado) (L) 411
- Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226
- Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (Blier) (L) 411
- The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

**Antipsychotic agents**
- Antipsychotic drugs cause glial cell lin e–derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res) 32
- The “delayed onset” of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93
- Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177
- The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

**Antipsychotic medications**
- The rational use of medications in acute psychotic presentations — the case for less is more (Awad) (Psychopharm) 216

**Anxiety**
- Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

**Atomoxetine**
- Treating depression with selective norepinephrine reuptake inhibitors (Blier) (Psychopharm) 288

**Attention deficit disorder with hyperactivity**
- Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial (Grizenko and others) (Res) 46

**Attribution bias**
- About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396

**Atypical antipsychotic agents**
- Treatment guidelines for mania (Kennedy) (Psychopharm) 144
<table>
<thead>
<tr>
<th>Topic</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auditory verbal hallucinations (AVH)</td>
<td></td>
</tr>
<tr>
<td>About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others)</td>
<td>(Res) 396</td>
</tr>
<tr>
<td>Biological psychiatry</td>
<td></td>
</tr>
<tr>
<td>Fewer classes of drugs for more and more psychiatric disorders</td>
<td></td>
</tr>
<tr>
<td>(Young) (E) 82</td>
<td></td>
</tr>
<tr>
<td>Bipolar disorder</td>
<td></td>
</tr>
<tr>
<td>The 29th Annual Meeting of the Canadian College of Neuro-psychopharmacology (Zawertailo and others) (CCNP)</td>
<td>413</td>
</tr>
<tr>
<td>Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res)</td>
<td>189</td>
</tr>
<tr>
<td>Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res)</td>
<td>326</td>
</tr>
<tr>
<td>Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res)</td>
<td>263</td>
</tr>
<tr>
<td>Treatment guidelines for mania (Kennedy) (Psychopharm) 144</td>
<td></td>
</tr>
<tr>
<td>Blotting</td>
<td></td>
</tr>
<tr>
<td>Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res)</td>
<td>105</td>
</tr>
<tr>
<td>Borderline personality disorder</td>
<td></td>
</tr>
<tr>
<td>“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res)</td>
<td>181</td>
</tr>
<tr>
<td>Brain</td>
<td></td>
</tr>
<tr>
<td>The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res)</td>
<td>246</td>
</tr>
<tr>
<td>“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res)</td>
<td>181</td>
</tr>
<tr>
<td>Brain imaging</td>
<td></td>
</tr>
<tr>
<td>Brain imaging and cognitive dysfunctions in Huntington’s disease (Montoya and others) (Rev)</td>
<td>21</td>
</tr>
<tr>
<td>Brain imaging (MRI)</td>
<td></td>
</tr>
<tr>
<td>The need for speed: an update on methamphetamine addiction (Barr and others) (Rev)</td>
<td>301</td>
</tr>
<tr>
<td>Breast feeding</td>
<td></td>
</tr>
<tr>
<td>Pregnancy, depression, antidepressants and breast-feeding (Blier) (E)</td>
<td>226</td>
</tr>
<tr>
<td>Bupropion</td>
<td></td>
</tr>
<tr>
<td>Psychopharmacology of smoking cessation in patients with mental illness (Selby) (Psychopharm)</td>
<td>360</td>
</tr>
<tr>
<td>Cell death</td>
<td></td>
</tr>
<tr>
<td>Antipsychotic drugs cause glial cell line–derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res)</td>
<td>32</td>
</tr>
<tr>
<td>Central nervous system</td>
<td></td>
</tr>
<tr>
<td>The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev)</td>
<td>229</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td></td>
</tr>
<tr>
<td>Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res)</td>
<td>271</td>
</tr>
<tr>
<td>Cholinesterase inhibitor</td>
<td></td>
</tr>
<tr>
<td>Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev)</td>
<td>369</td>
</tr>
<tr>
<td>Clinical trials</td>
<td></td>
</tr>
<tr>
<td>Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res)</td>
<td>38</td>
</tr>
<tr>
<td>Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E)</td>
<td>13</td>
</tr>
<tr>
<td>Cocaine-related disorders</td>
<td></td>
</tr>
<tr>
<td>Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res)</td>
<td>115</td>
</tr>
<tr>
<td>Cognition</td>
<td></td>
</tr>
<tr>
<td>Brain imaging and cognitive dysfunctions in Huntington’s disease (Montoya and others) (Rev)</td>
<td>21</td>
</tr>
<tr>
<td>Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev)</td>
<td>369</td>
</tr>
<tr>
<td>“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res)</td>
<td>181</td>
</tr>
<tr>
<td>Corollary discharge, SMA</td>
<td></td>
</tr>
<tr>
<td>About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res)</td>
<td>396</td>
</tr>
<tr>
<td>Cyclic AMP</td>
<td></td>
</tr>
<tr>
<td>The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res)</td>
<td>246</td>
</tr>
<tr>
<td>Dementia</td>
<td></td>
</tr>
<tr>
<td>Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev)</td>
<td>369</td>
</tr>
<tr>
<td>Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm)</td>
<td>72</td>
</tr>
<tr>
<td>The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Light and Holroyd) (Brief)</td>
<td>132</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
</tr>
<tr>
<td>Depression in acute stroke (Caeiro and others) (Res)</td>
<td>377</td>
</tr>
<tr>
<td>Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res)</td>
<td>38</td>
</tr>
<tr>
<td>Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res)</td>
<td>101</td>
</tr>
<tr>
<td>Is the thyroid still important in major depression? (Joffe) (E)</td>
<td>367</td>
</tr>
<tr>
<td>Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm)</td>
<td>414</td>
</tr>
<tr>
<td>Pregnancy, depression, antidepressants and breast-feeding (Blier) (E)</td>
<td>226</td>
</tr>
<tr>
<td>Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frod and others) (Res)</td>
<td>316</td>
</tr>
<tr>
<td>Treating depression with selective norepinephrine reuptake inhibitors (Blier) (Psychopharm)</td>
<td>288</td>
</tr>
<tr>
<td>Depressive disorder, major</td>
<td></td>
</tr>
<tr>
<td>Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res)</td>
<td>122</td>
</tr>
<tr>
<td>The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev)</td>
<td>168</td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm)</td>
<td>414</td>
</tr>
<tr>
<td>Discontinuation</td>
<td></td>
</tr>
<tr>
<td>Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm)</td>
<td>72</td>
</tr>
</tbody>
</table>
Index to Volume 31

Disinhibition
The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behavior in patients with dementia (Light and Holroyd) (Brief) 132

Donepezil
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev) 369
Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

Dopamine
The 29th Annual Meeting of the Canadian College of Neuropsychopharmacology (Zawertailo and others) (CCNP) 413
The rational use of medications in acute psychotic presentations – the case for less is more (Awad) (Psychopharm) 216
The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

Dopamine antagonists
The “delayed onset” of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93

Dopaminergic system
Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326

Drug therapy
The “delayed onset” of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93

Dyskinesias
Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

Dystonia
Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

Electroencephalography
“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res) 181

Electron transport
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

Emotions
Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

Environment
Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

Escitalopram
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

Estrogen
Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

Evoked potentials
Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res) 263

Executive memory
Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frodl and others) (Res) 316

Extrapyramidal symptoms
Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

Functional neuroimaging
Brain imaging and cognitive dysfunctions in Huntington’s disease (Montoya and others) (Rev) 21

Gamma synchrony
“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res) 181

Gene expression
Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects (Little and others) (Res) 333

Genetics
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189
Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

Glial cell line–derived neurotrophic factor
Antipsychotic drugs cause glial cell line–derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res) 32

Glutamate
The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

Glutamine
The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

Haloperidol
Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271

Happiness
Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

Heart rate
Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386

Heroin dependence
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Hippocampus
Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frodl and others) (Res) 316

Huntington disease
Brain imaging and cognitive dysfunctions in Huntington’s disease (Montoya and others) (Rev) 21

Hypertension
Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

Immunohistochemistry
Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105
Index au volume 31

Inositol-1,4,5-triphosphate (IP3)
The effect of lithium on the adrenocceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

Interpersonal relations
Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13

Language
A rant against jargon and neologisms (Young) (E) 155

Learning disorders
Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial (Grizenko and others) (Res) 46

Levomepromazine
Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271

Lexical processing
About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephan and others) (Res) 396

Lithium
The effect of lithium on the adrenocceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246
Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189
Is the thyroid still important in major depression? (Joffe) (E) 367

MADRS
Depression in acute stroke (Caeiro and others) (Res) 377

Magnetic resonance spectroscopy
The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

Mania
Treatment guidelines for mania (Kennedy) (Psychopharm) 144

Methoxypregosterone acetate
The use of methoxypregosterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Light and Holroyd) (Brief) 132

Memantine
 Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

Memory
Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

Meta-analysis
The 29th Annual Meeting of the Canadian College of Neuropsychopharmacology (Zawertailo and others) (CCNP) 413
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

Metabolic syndrome
Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

Methamphetamine
The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

Methylphenidate
Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial (Grizenko and others) (Res) 46

Mitochondria
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

Models, animal
Antipsychotic drugs cause glial cell line–derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res) 32
Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

Mood disorders
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Movement disorders
Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

Naltrexone
Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Narcotic antagonists
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Neuroleptic dysphoria
The rational use of medications in acute psychotic presentations — the case for less is more (Awad) (Psychopharm) 216

Neurotensin
The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

NF-kappa B
Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

Norepinephrine
Treating depression with selective norepinephrine reuptake inhibitors (Blier) (Psychopharm) 288

Off-label indications
The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

Orbitofrontal cortex
Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res) 263
Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101
Index to Volume 31

-P-

Parkinson disease
Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296
The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

Parkinsonian disorders
Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

Pathophysiology
The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

PET
About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396

Physiopathology
Fewer classes of drugs for more and more psychiatric disorders (Young) (E) 82

Plasma
The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

Polymerase chain reaction
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

Prefrontal cortex
The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

Pregnancy
Concerns regarding antidepressant use during pregnancy (Uratu) (L) 411
Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226
Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (Blier) (L) 411

Pregnancy complications
Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

Progesterone
Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

Psychology, social
Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13

Psychopharmacology
Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326
Fewer classes of drugs for more and more psychiatric disorders (Young) (E) 82
Psychopharmacology of smoking cessation in patients with mental illness (Selby) (Psychopharm) 360

Psychoses
The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

Publishing
A rant against jargon and neologisms (Young) (E) 155

-Q-

QT-interval
Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

Radionuclide binding
The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

Rats
The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

Research
Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13
A rant against jargon and neologisms (Young) (E) 155

Reuptake inhibitors
Treating depression with selective norepinephrine reuptake inhibitors (Blier) (Psychopharm) 288

Reverse transcriptase polymerase chain reaction
Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

-S-

Safety
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Schizoaffective disorders
Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

Schizophrenia
About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev) 369
The "delayed onset" of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93
Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177
Levodopa versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271
The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406
The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229
Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157
The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

Serotonergic mechanisms
Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects (Little and others) (Res) 333
Serotonin
Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105
Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253
Serotonin uptake inhibitors
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

Sexual disorder
The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Light and Holroyd) (Brief) 132

Smell
Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res) 263

Smoking cessation
Psychopharmacology of smoking cessation in patients with mental illness (Selby) (Psychopharm) 360

Social behaviour
Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

Social perception
Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

SSRIs
Concerns regarding antidepressant use during pregnancy (Uratou) (L) 411
Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (Blier) (L) 411

Stimulant
Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386

Stroke, acute
Depression in acute stroke (Caeiro and others) (Res) 377

Structural MRI
Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frodl and others) (Res) 316

Structural neuroimaging
Brain imaging and cognitive dysfunctions in Huntington’s disease (Montoya and others) (Rev) 21

Substance-related disorders
Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res) 115

Substance use disorders
The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

Terminology
A rant against jargon and neologisms (Young) (E) 155

Therapeutics
Fewer classes of drugs for more and more psychiatric disorders (Young) (E) 82
Transcranial magnetic stimulation, increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

Thyroid
Is the thyroid still important in major depression? (Joffe) (E) 367

Treatment outcome
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

Treatment resistance
Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271

Tricyclic antidepressants
Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

Tryptophan
Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

Author / Auteurs

-A-
aan het Rot M, Moskowitz DS, Pinard G, Young SN
Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (Res) 253

Agbokou C See Ferreri F Jt Auth
Agid O, Seeman P, Kapur S
The “delayed onset” of antipsychotic action — an idea whose time has come and gone (Rev) 93

Andersen HF See Kennedy SH Jt Auth
Annable L See Lal S Jt Auth

Awad AG
The rational use of medications in acute psychotic presentations — the case for less is more (Psychopharm) 216

-B-

Baker G See Shulman Y Jt Auth
Banac S See Frodl T Jt Auth
Bardini K See Frey BN Jt Auth
Barr AM, Penanaka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T
The need for speed: an update on methamphetamine addiction (Rev) 301

Bethea CL, Reddy AP, Smith LJ
Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Res) 105

Bhat M See Grizenko N Jt Auth

Bliesz P
Pregnancy, depression, antidepressants and breast-feeding (E) 226
Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (L) 411
Treating depression with selective norepinephrine reuptake inhibitors (Psychopharm) 288

Born C See Frodl T Jt Auth

Bottlinger R See Frodl T Jt Auth

Bräunig P See Krüger S Jt Auth

-C-

Caeiro L, Ferro JM, Santos CO, Figueira ML
Depression in acute stroke (Res) 377

Casey KF See Zawertailo L Jt Auth

Charypar M See Frodl T Jt Auth

Chokka P, Tancer M, Yeragani VK
Metabolic syndrome: relevance to antidepressant treatment (Psychopharm) 414

Chouinard G
Interrelations between psychiatric symptoms and drug-induced movement disorder (Rev) 177
The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Rev) 168
Christie BR See Ernst C Jt Auth
Connor JP See Dean AJ Jt Auth
Conrod P See Peterson JB Jt Auth
Cook E See Little KY Jt Auth

Dal-Pizzol F See Frey BN Jt Auth
Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Res) 38

Devaki R, Shankar Rao S, Nadgir SM
The effect of lithium on the adrenoreceptor-mediated second messenger system in the rat brain (Res) 246

Dyk LE See Shao Z Jt Auth

Ernst C, Olson AK, Pinel JPJ, Lam RW, Christie BR
Antidepressant effects of exercise: Evidence for an adult-neurogenesis hypothesis? (Rev) 84

Ferreri F, Agbokou C, Gauthier S
Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Rev) 369

Frey BN See Caeiro L Jt Auth
Figueira ML See Caeiro L Jt Auth
Flores C See Zawertailo L Jt Auth
Frasnelli J See Krüger S Jt Auth

Gabriel A See Lal S Jt Auth
Gauthier S
Managing discontinuation syndrome in patients with dementia (Psychopharm) 72

Gauthier S See Ferreri F Jt Auth
Gianoulakis C See Peterson JB Jt Auth
Gordon E See Williams LM Jt Auth
Grant S See Shulman Y Jt Auth

Grzenko N, Bhat M, Schwartz G, Ter-Stephanian M, Joobr R
Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial (Res) 46

Hagen MC See Stephane M Jt Auth
Hanstock C See Shulman Y Jt Auth
Holroyd S See Light SA Jt Auth
Honer WG See Barr AM Jt Auth
Hori SE See Robertson JS Jt Auth
Hummel T See Krüger S Jt Auth

Jäger M See Frodl T Jt Auth
Joffe RT
Discontinuing treatment for psychiatric disorders (E) 11
Is the thyroid still important in major depression? (E) 367

Jomphe C See St-Gelais F Jt Auth
Jones RT See Dean AJ Jt Auth
Joobr R See Grzenko N Jt Auth

Kapur S See Agid O Jt Auth
Kennedy SH
Treatment guidelines for mania (Psychopharm) 144

Kennedy SH, Andersen HF, Lam RW
Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Res) 122

Krüger S, Frasnelli J, Bräunig P, Hummel T
Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Res) 263

Kümmler P See Frodl T Jt Auth
Kuskowski M See Stephane M Jt Auth

Lal S, Thavundayil JX, Nair NPV, Annable L, Ng Ying Kin NMK, Gabriel A, Schwartz G
Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Res) 271

Lam RW See Ernst C Jt Auth; Kennedy SH Jt Auth
Lang DJ See Barr AM Jt Auth
Lawford BR See Dean AJ Jt Auth
Lecomte T See Barr AM Jt Auth
Lee JT See Stephane M Jt Auth
Leinsinger G See Frodl T Jt Auth
Lepage M See Montoya A Jt Auth
Leyton M See Zawertailo L Jt Auth
Li CSR, Sinha R
Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Res) 115

Li XM See Shao Z Jt Auth
Light SA, Holroyd S
The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Brief) 132

Little KY, Zhang L, Cook E
Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects (Res) 333

MacEwan GW See Barr AM Jt Auth
Martins MR See Frey BN Jt Auth
Meares RA See Williams LM Jt Auth
Meisenzal EM See Frodl T Jt Auth
Menear M See Montoya A Jt Auth
Möller HJ See Frodl T Jt Auth
Montoya A, Price BH, Menear M, Lepage M
Brain imaging and cognitive dysfunctions in Huntington’s disease (Rev) 21
Moskowitz DS See aan het Rot M Jt Auth
Moskowitz DS, Young SN
Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Comm) 13

-N-
Nadgir SM See Devaki R Jt Auth
Nair NPV See Lal S Jt Auth
Ng Ying Kin NMK See Lal S Jt Auth

-O-
Olson AK See Ernst C Jt Auth

-P-
Panenka WJ See Barr AM Jt Auth
Pardo JV See Stephane M Jt Auth
Pardo PJ See Stephane M Jt Auth
Peterson JB, Conrod P, Vassileva J, Gianoulakis C, Pihl RO
Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Res) 386
Petronilho FC See Frey BN Jt Auth
Pihl RO See Peterson JB Jt Auth
Pinard G See aan het Rot M Jt Auth
Pinel JPJ See Ernst C Jt Auth
Powell KJ See Robertson GS Jt Auth
Price BH See Montoya A Jt Auth

-Q-
Quevedo J See Frey BN Jt Auth

-R-
Reddy AP See Bethea CL Jt Auth
Reiser M See Frodl T Jt Auth
Réus GZ See Frey BN Jt Auth
Robertson GS, Horri SE, Powell KJ
Schizophrenia: an integrative approach to modelling a complex disorder (Rev) 157
Santos CO See Caeiro L Jt Auth
Saunders JB See Dean AJ Jt Auth
Schaub A See Frodl T Jt Auth
Schutter DJLG, van Honk J
Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Res) 101
Schwartz G See Grzenko N Jt Auth; Lal S Jt Auth
Seeman P See Agid O Jt Auth
Selby P
Psychopharmacology of smoking cessation in patients with mental illness (Psychopharm) 360
Seret P See Shulman Y Jt Auth
Shankar Rao S See Devaki R Jt Auth
Shao Z, Dyck LE, Wang H, Li XM
Antipsychotic drugs cause glial cell line–derived neurotrophic factor secretion from C6 glioma cells (Res) 32
Shulman Y, Grant S, Seres P, Hansstock C, Baker G, Tibbo P
The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Brief) 406
Sidis A See Williams LM Jt Auth
Sinha R See Li CSR Jt Auth

-Smith LJ See Bethea CL Jt Auth
St-Gelais F, Jomphe C, Trudeau LÉ
The role of neotensin in central nervous system pathophysiology: What is the evidence? (Rev) 229
Stephane M, Hagen MC, Lee JT, Uecker J, Pardo PJ, Kuskowski M, Pardo JV
About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Res) 396
Sun X, Wang JF, Tseng M, Young LT
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Res) 189

-T-
Tancer M See Chokka P Jt Auth
Ter-Stepanian M See Grzenko N Jt Auth
Thavundayil JX See Lal S Jt Auth
Thornton AE See Barr AM Jt Auth
Tibbo P See Shulman Y Jt Auth
Trudeau LÉ See St-Gelais F Jt Auth
Tseng M See Sun X Jt Auth

-U-
Uecker J See Stephane M Jt Auth
Urato AC
Concerns regarding antidepressant use during pregnancy (L) 411

-V-
Valvassori SS See Frey BN Jt Auth
van Honk J See Schutter DJLG Jt Auth
Vassileva J See Peterson JB Jt Auth

-W-
Wang H See Shao Z Jt Auth
Wang JF See Sun X Jt Auth
Williams LM, Sidis A, Gordon E, Meares RA
“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (Res) 181
Wood PL
Neurodegeneration and aldehyde load: from concept to therapeutics (E) 296

-Y-
Yeragani VK See Chokka P Jt Auth
Young LT
Fewer classes of drugs for more and more psychiatric disorders (E) 82
Young LT See Sun X Jt Auth
Young RM See Dean AJ Jt Auth
Young SN
A rant against jargon and neologisms (E) 155
Young SN See aan het Rot M Jt Auth; Moskowitz DS Jt Auth

-Z-
Zawertailo L, Casey KE, Leyton M, Flores C
The 29th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP) 413
Zetzche T See Frodl T Jt Auth
Zhang L See Little KY Jt Auth